FDA Adverse Event Malfunction Summary report: N

BD MAX¿ ENTERIC VIRAL PANEL

MDR report key: 24261920 · Received February 4, 2026

Report

Report Number
3007420875-2026-00005
Event Type
Malfunction
Date Received
February 4, 2026
Date of Event
October 30, 2025
Report Date
February 4, 2026
Manufacturer
GENEOHM SCIENCES CANADA, INC. (BD DIAGNOSTICS)
Product Code
OOI
UDI-DI
00382904439859
PMA / PMN Number
K220607
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
NZ
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION SUMMARY: THE COMPLAINT INVESTIGATION FOR DISCREPANT RESULTS WITH THE BD MAX¿ ENTERIC VIRAL PANEL KIT REF.(B)(4), LOT 5021182 WAS PERFORMED BY THE REVIEW OF MANUFACTURING RECORDS, CUSTOMER¿S DATA ANALYSIS AND VERIFICATION OF COMPLAINTS HISTORY. THE REVIEW OF QUALITY CONTROL RECORDS OF BD MAX¿ ENTERIC VIRAL PANEL KIT LOT 5021182 REVEALED NO ANOMALIES THAT COULD EXPLAIN THE CUSTOMER¿S DISCREPANT RESULTS. CUSTOMER REPORTED AN INCREASE IN POSITIVE RESULTS THAT WERE FOUND TO BE MOSTLY FALSE POSITIVE RESULTS AND PROVIDED RUN FILES (PDF AND CSV) OF RUN 1302 FROM BD MAX¿ INSTRUMENT CT2482 FOR INVESTIGATION. NO SAMPLES WERE IDENTIFIED BY THE CUSTOMER. THE SIX POSITIVE SAMPLES FOUND IN RUN 1302 WERE ANALYZED (B5, B6, B8, B9, B10, B11). MANUAL PCR CURVE ADJUDICATION SHOWED TRUE AMPLIFICATION FOR SAMPLE B5 IN THE FAM CHANNEL IN THE TOP POSITION OF THE CARTRIDGE (ROTAVIRUS (ROV) TARGET), SAMPLE B6 IN THE VIC CHANNEL IN BOTTOM POSITION OF THE CARTRIDGE (SAPOVIRUS (SAV) TARGET) AND SAMPLES B8/B9 IN THE FAM CHANNEL IN TOP POSITION OF THE CARTRIDGE (ROTAVIRUS (ROV) TARGET). HOWEVER, PRELIMINARY ANALYSIS FOR SAMPLES B8 TOP (ADENOVIRUS (ADV) TARGET) AND B9 TOP/BOTTOM (ADV AND SAV TARGETS RESPECTIVELY) SUGGESTS A POSSIBLE OPTICAL CROSSTALK ISSUE. IT IS UNLIKELY THESE POSITIVE RESULTS (B8 ADV POS AND B9 ADV AND SAV POS RESULTS) ARE TRUE AMPLIFICATIONS. THIS INFORMATION WAS TRANSFERRED TO BD SERVICE FOR FURTHER INVESTIGATION, AND A SERVICE CASE HAS BEEN OPENED ON THE INSTRUMENT CT2482. SAMPLES B10 AND B11, ON THE OTHER HAND, SHOWED STEP DISLOCATIONS IN MULTIPLE CHANNELS RESULTING IN FLUORESCENCE REACHING THE THRESHOLD TO GIVE A POSITIVE RESULT IN THE ROX CHANNEL, IN BOTTOM (ASTROVIRUS (HASTV) TARGET) AND TOP (NOROVIRUS (NOV) TARGET) POSITIONS OF THE CARTRIDGE, RESPECTIVELY. IT IS UNLIKELY THESE POSITIVE RESULTS ARE TRUE AMPLIFICATIONS. UNFORTUNATELY, NO ROOT CAUSE COULD BE IDENTIFIED BUT THE ISSUE SEEMED ISOLATED TO THESE TWO EVENTS. NEVERTHELESS, IT MUST BE NOTED THAT MANUAL CURVE ADJUDICATION HAS LIMITATIONS; VISUAL EXAMINATION OF PCR CURVES FOR LOW SIGNAL AND ABERRANT CURVE GEOMETRY ARE A CONSERVATIVE ASSESSMENT OF THE DATA. OVERALL, BASED ON THE DATA PROVIDED, BD WAS UNABLE TO FIND THE EXACT CAUSE OF WHY SOME OF THE CUSTOMER¿S POSITIVE RESULTS APPEAR TO BE FALSE. THERE IS NO INDICATION OF A REAGENT ISSUE BASED ON THE ANALYSIS OF THE COMPLAINTS RECEIVED FOR DISCREPANT RESULTS ON BD MAX¿ ENTERIC VIRAL PANEL ASSAY LOT 5021182. THE ROOT CAUSE WAS NOT IDENTIFIED. BD CANNOT CONFIRM THE COMPLAINT BASED ON THE INVESTIGATION THAT WAS PERFORMED. BD DID NOT INITIATE A CORRECTIVE AND PREVENTIVE ACTION (CAPA) SINCE NO NEW HAZARD WAS IDENTIFIED.

Description of Event or Problem · 0

REPORT 3 OF 6: IT WAS REPORTED THAT DURING USE OF BD MAX¿ ENTERIC VIRAL PANEL, A FALSE POSITIVE PATIENT RESULT WAS OBTAINED. THERE WAS NO REPORT OF PATIENT IMPACT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
322370 BD MAX¿ ENTERIC VIRAL PANEL GASTROINTESTINAL PATHOGEN PANEL MULTIPLEX NUCLEIC ACID-BASED ASSAY SYSTEM OOI GENEOHM SCIENCES CANADA, INC. (BD DIAGNOSTICS) 5021182 00382904439859

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown